Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Genus now sits against a refreshed price target, with analysts pointing to a £1.00 uplift that tracks closely with updated fair value work at £31.63. Bullish and bearish voices alike are tying this shift to how robust they think the assumptions are, particularly around the durability of the fair value that underpins the new target. As you read on, you will see how to interpret these moving parts and keep up with the evolving analyst narrative around Genus.
Stay updated as the Fair Value for Genus shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Genus.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Berenberg, through analyst Robert, has raised its Genus price target by 100 GBp. This aligns closely with the refreshed fair value work around £31.63 and supports the idea that recent assumptions are reflected in formal research.
-
The Berenberg move signals that at least one covering firm sees the current valuation framework as supportable. The higher target points to confidence in Genus' ability to execute against the drivers embedded in that fair value estimate.
🐻 Bearish Takeaways
-
Even with the 100 GBp uplift from Berenberg, the focus on detailed fair value work highlights how sensitive the investment case can be to changes in key inputs such as growth expectations, margin profiles, or capital intensity.
-
The reliance on a single, updated target from Berenberg underlines that the wider analyst debate on Genus is still relatively thin. This can leave readers with less cross check on assumptions and a wider potential range of outcomes around valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Genus. See which could impact your investment.
What's in the News
-
Genus formed its Chinese porcine joint venture with Beijing Capital Agribusiness on 31 January 2026. Genus is set to receive a gross cash payment of US$160 million, estimated at about US$140 million net after tax and transaction costs, plus a previously recognised US$7.5 million milestone payment. PIC China will be deconsolidated from group accounts.
-
Management plans to outline the pro forma impact of the Chinese joint venture structure at the interim results on 26 February 2026. This will cover how the deal affects reported numbers and segment exposure.
-
Canada approved use of Genus's PRP gene edit after several years of work with regulators. The company views this as an important step toward potential PRP commercialisation in North America, while it continues to pursue approvals in markets such as Mexico, Japan and China.
-
Health Canada and the Canadian Food Inspection Agency concluded that Genus's PRRSV resistant pigs are safe for use in food and livestock feed. Genus does not plan to sell these pigs in Canada until further authorisations are in place in other key markets and Canadian authorities finish reviewing labelling standards for genetically engineered foods.
How This Changes the Fair Value For Genus
-
Fair Value is set at £31.63 compared with the prior £31.67, reflecting a very small recalibration in the model.
-
Revenue Growth is now assumed at 3.70% compared with 4.10% previously, indicating a slightly more cautious stance on the top line outlook.
-
Net Profit Margin is updated to 9.02% from 9.02%, so earnings quality assumptions are effectively unchanged.
-
Future P/E is now set at 38.48x versus 38.06x previously, a small uplift in the valuation multiple used.
-
The Discount Rate has been adjusted to 7.59% from 7.60%, a very modest change in the risk and return inputs.
Never Miss an Update: Follow The Narrative
Narratives connect Genus' business story to the assumptions behind analyst forecasts and fair value work, so you can see what is driving the numbers. They refresh as new data, deals, and regulatory decisions come through.
Head over to the Simply Wall St Community and follow the Narrative on Genus to stay up to date on:
-
How growth in the porcine division and China partnerships are expected to shape revenue and earnings.
-
What the Value Acceleration Program and ABS De Novo acquisition could mean for bovine margins and cash generation.
-
Key risks around weaker pig prices in China, FX headwinds in Latin America, and possible delays in PRP regulatory approvals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GNS.L .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
